News

08 January 2019

DiaSorin launches Simplexa Bordetella Direct molecular test in the United States

DiaSorin received FDA clearance for its new Bordetella molecular diagnostic test designed to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in human nasopharyngeal swabs.

04 January 2019

Biogem, a new important contribution to oncology scientific research

21 December 2018

Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Recordati announced that the FDA has granted Orphan Drug Designation to Recordati Rare Disease’s investigational product REC 0559 for the treatment of neurotrophic keratitis

14 December 2018

Bio-on and Hera create lux-on: the new challenge to produce bioplastic from CO2

Bio-on and Gruppo Hera have reached an agreement in LUX-ON, the new company aiming to revolutionise the production of PHAs biopolymers using CO2 captured from the atmosphere and producing energy without using fossil fuels.

05 December 2018

Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease

Announced the recent approval of Xadago®/safinamide in Australia by the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the treatment of adult patients with fluctuating idiopathic Parkinson’s disease (PD)

20 November 2018

Diasorin launches Simplexa Group B Strep Direct molecular assay in the United States

DiaSorin announced to have received FDA clearance for its new Simplexa Group B Strep Direct recently launched in the European market

1 2 3 4 5

20149 Milan
Via Giovanni da Procida, 11
Show map

Tel. +39 02.34565.1
Fax. +39 02.34565.310

Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it